Pertussis in Children

Topic Name Introduction Epidemiology Pathogenesis Clinical Presentation Diagnosis Treatment Complications Prevention B. parapertussis

Introduction to Pertussis in Children

Pertussis, also known as whooping cough, is a highly contagious respiratory disease primarily caused by the bacterium Bordetella pertussis. Less commonly, it can be caused by Bordetella parapertussis. Pertussis remains a significant public health concern, particularly for infants and young children, despite widespread vaccination efforts.

Key Points:

• Caused primarily by Bordetella pertussis, a gram-negative coccobacillus
• Transmission occurs through respiratory droplets
• Characterized by paroxysmal coughing fits, often followed by a distinctive "whooping" sound
• Most severe in infants, especially those under 6 months of age
• Can occur in vaccinated individuals, but usually with milder symptoms
• B. parapertussis causes a similar but typically milder illness

Understanding the clinical features, diagnosis, and management of pertussis is crucial for healthcare providers, as early recognition and treatment can significantly impact disease course and prevent complications, especially in young children.

Epidemiology of Pertussis

Global Burden:

• Worldwide, an estimated 24.1 million cases and 160,700 deaths in children <5 years (WHO, 2014)
• Resurgence noted in several countries despite high vaccination coverage

Age Distribution:

• Highest incidence and mortality in infants <1 year, especially <6 months
• Increasing incidence in adolescents and adults, who serve as reservoirs

Transmission:

• Highly contagious: attack rates up to 90% in susceptible household contacts
• Spread through respiratory droplets or direct contact with respiratory secretions
• Most infectious during catarrhal and early paroxysmal stages

Seasonal Variation:

• Peak incidence typically in late summer and early fall in temperate climates
• Can occur year-round, with outbreaks possible at any time

Vaccine Impact:

• Significant reduction in incidence and mortality since introduction of vaccines
• Shift in age distribution towards adolescents and adults due to waning immunity
• Emergence of vaccine-escape strains reported in some regions

Pathogenesis of Pertussis

Bacterial Factors:

• Adhesins:
  • Filamentous hemagglutinin (FHA)
  • Pertactin (PRN)
  • Fimbriae (FIM)
• Toxins:
  • Pertussis toxin (PT): Key virulence factor, causes lymphocytosis
  • Adenylate cyclase toxin (ACT): Impairs neutrophil function
  • Tracheal cytotoxin (TCT): Damages respiratory epithelium

Stages of Infection:

1. Attachment: Adhesins facilitate binding to ciliated respiratory epithelial cells
2. Evasion of host defenses: Toxins impair immune response
3. Local damage: Ciliary paralysis and epithelial damage
4. Systemic effects: PT-induced lymphocytosis and other systemic manifestations

Host Immune Response:

• Initially dominated by innate immune responses
• Adaptive immunity develops, with both humoral and cell-mediated components
• Immunity after natural infection wanes over time (5-10 years)

Factors Influencing Severity:

• Age: Most severe in young infants due to immature immune systems
• Vaccination status: Vaccinated individuals typically have milder disease
• Comorbidities: Underlying conditions may increase risk of severe disease

Clinical Presentation of Pertussis

Classic Stages:

1. Catarrhal Stage (1-2 weeks):
   • Mild upper respiratory symptoms (rhinorrhea, low-grade fever)
   • Gradual onset of cough
   • Highly contagious during this stage
2. Paroxysmal Stage (2-6 weeks):
   • Characteristic paroxysmal coughing fits
   • Post-tussive vomiting
   • Inspiratory "whoop" in some cases
   • Cyanosis or apnea, especially in infants
3. Convalescent Stage (weeks to months):
   • Gradual resolution of symptoms
   • Persistent cough may last for weeks to months

Age-Specific Presentations:

• Infants (<6 months):
  • May not exhibit classic "whoop"
  • Apnea, cyanosis, and feeding difficulties more common
  • Higher risk of severe complications
• Older Children and Adolescents:
  • May have milder symptoms, especially if vaccinated
  • Prolonged cough often the primary symptom

Atypical Presentations:

• Vaccinated individuals may have milder, nonspecific symptoms
• Consider pertussis in any prolonged cough illness, especially if paroxysmal

Diagnosis of Pertussis

Clinical Diagnosis:

• Based on characteristic cough and associated symptoms
• World Health Organization (WHO) clinical case definition:
  • Cough lasting ≥2 weeks with at least one of:
    • Paroxysms of coughing
    • Inspiratory "whoop"
    • Post-tussive vomiting

Laboratory Diagnosis:

• Polymerase Chain Reaction (PCR):
  • Most sensitive and specific method
  • Rapid results (within 24-48 hours)
  • Can detect non-viable organisms
• Culture:
  • Gold standard, but less sensitive than PCR
  • Requires special media (Regan-Lowe or Bordet-Gengou)
  • Results take 7-10 days
• Serology:
  • Useful in later stages of illness
  • Single high anti-PT IgG titer or significant rise in titer
  • Limited utility in vaccinated individuals

Other Investigations:

• Complete Blood Count: May show characteristic lymphocytosis
• Chest X-ray: Often normal, may show perihilar infiltrates or atelectasis

Differential Diagnosis:

• Other causes of prolonged cough: Mycoplasma, Chlamydophila, viral infections
• Cystic fibrosis
• Foreign body aspiration
• Asthma or reactive airway disease

Treatment of Pertussis

Antimicrobial Therapy:

• Primary goals: Reduce transmission and modify course if given early
• Recommended antibiotics:
  • Azithromycin: First-line for all ages
    • <6 months: 10 mg/kg once daily for 5 days
    • ≥6 months: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg (max 250 mg) on days 2-5
  • Clarithromycin: Alternative for ≥1 month old
    • 15 mg/kg/day in 2 divided doses (max 1 g/day) for 7 days
  • Trimethoprim-sulfamethoxazole: Alternative for ≥2 months old
    • 8 mg/kg/day trimethoprim, 40 mg/kg/day sulfamethoxazole in 2 doses for 14 days

Supportive Care:

• Hospitalization often required for infants <6 months or those with severe disease
• Oxygen therapy and suctioning as needed
• Maintain hydration and nutrition
• Monitor for apnea, especially in young infants

Management of Complications:

• Pneumonia: Additional antibiotics if bacterial superinfection suspected
• Seizures: Anticonvulsant therapy as indicated
• Respiratory failure: May require mechanical ventilation

Additional Considerations:

• Avoid antitussives (ineffective and potentially harmful)
• Corticosteroids: Not routinely recommended, may be considered in severe cases
• Close monitoring of infants, especially those <6 months

Complications of Pertussis

Respiratory Complications:

• Pneumonia: Most common severe complication
  • Can be primary (due to B. pertussis) or secondary bacterial infection
  • Occurs in up to 20% of infants <6 months
• Atelectasis
• Pneumothorax or pneumomediastinum (rare)
• Respiratory failure requiring mechanical ventilation

Neurologic Complications:

• Seizures: Due to hypoxia or pertussis encephalopathy
• Encephalopathy: Rare but serious
  • May lead to long-term neurological sequelae
  • Exact mechanism unclear (hypoxia, toxin effect, or hemorrhage)
• Intracranial hemorrhage: From increased intracranial pressure during coughing

Other Complications:

• Nutritional: Weight loss, dehydration
• Musculoskeletal: Rib fractures (rare, usually in adults)
• Urinary incontinence
• Subconjunctival hemorrhage
• Umbilical or inguinal hernia

Long-term Sequelae:

• Persistent cough (for weeks to months)
• Decreased lung function (usually transient)
• Neurological sequelae in cases of severe encephalopathy

Mortality:

• Highest in infants <6 months
• Main causes: Pneumonia, refractory pulmonary hypertension, cardiac failure

Prevention of Pertussis

Vaccination:

• Primary prevention strategy
• Types of vaccines:
  • DTaP (Diphtheria, Tetanus, acellular Pertussis): For children <7 years
  • Tdap (Tetanus, diphtheria, acellular pertussis): For adolescents and adults
• Recommended schedule (USA):
  • DTaP: 5-dose series at 2, 4, 6, 15-18 months, and 4-6 years
  • Tdap: Single dose at 11-12 years
  • Pregnant women: Tdap with each pregnancy (preferably at 27-36 weeks gestation)
• Vaccine efficacy:
  • ~80-90% after 3-dose primary series
  • Waning immunity over time, especially with acellular vaccines

Chemoprophylaxis:

• Recommended for high-risk close contacts of pertussis cases
• Same antibiotics and dosing as treatment
• Prioritize:
  • Household contacts
  • Infants and their household members
  • Pregnant women in their third trimester
  • Individuals with pre-existing health conditions at risk for severe illness

Infection Control Measures:

• Droplet precautions for hospitalized patients
• Exclusion from school/childcare until 5 days of appropriate antibiotic therapy completed
• Encourage good respiratory hygiene and hand washing

Public Health Strategies:

• Surveillance and rapid case identification
• Contact tracing and management
• Education of healthcare providers and the public
• Promotion of vaccination, including "cocooning" strategy (vaccinating close contacts of infants)

Bordetella parapertussis Infections

Overview:

• Causes a pertussis-like illness, generally milder than B. pertussis
• Accounts for 5-20% of pertussis-like infections in some populations

Key Differences from B. pertussis:

• Does not produce pertussis toxin
• Often shorter duration of illness
• Less likely to cause severe complications

Clinical Presentation:

• Similar to B. pertussis but typically milder
• May be indistinguishable from pertussis in some cases
• Paroxysmal cough and post-tussive vomiting can occur

Diagnosis:

• PCR: Can differentiate B. parapertussis from B. pertussis
• Culture: Grows on standard Bordetella media
• Serology: Limited utility due to cross-reactivity with B. pertussis

Treatment:

• Similar to B. pertussis
• Macrolides (azithromycin, clarithromycin) are first-line
• Supportive care as needed

Prevention:

• Current pertussis vaccines do not provide protection against B. parapertussis
• Similar infection control measures as for B. pertussis

Public Health Implications:

• May be underdiagnosed due to milder presentation
• Can circulate in highly vaccinated populations
• Importance of species-specific diagnosis for accurate epidemiological data

Objective QnA: Pertussis (B. pertussis and parapertussis) in Children

1. Question: What is the causative agent of pertussis? Answer: Bordetella pertussis and, less commonly, Bordetella parapertussis
2. Question: What is the typical incubation period for pertussis? Answer: 7-10 days, with a range of 5-21 days
3. Question: What are the three classic stages of pertussis? Answer: Catarrhal stage, paroxysmal stage, and convalescent stage
4. Question: What is the characteristic sound associated with pertussis cough? Answer: Inspiratory "whoop"
5. Question: In which age group is pertussis most severe and potentially fatal? Answer: Infants under 6 months of age
6. Question: What is the recommended method for diagnosing pertussis in the first 2-3 weeks of illness? Answer: PCR testing of nasopharyngeal specimens
7. Question: What is the first-line antibiotic treatment for pertussis in children? Answer: Azithromycin
8. Question: How long is the typical duration of the paroxysmal stage in pertussis? Answer: 1-6 weeks, sometimes longer
9. Question: What is the most common complication of pertussis in infants? Answer: Pneumonia
10. Question: What is the recommended post-exposure prophylaxis for household contacts of pertussis cases? Answer: Antibiotic treatment, regardless of vaccination status
11. Question: What is the composition of the DTaP vaccine? Answer: Diphtheria toxoid, tetanus toxoid, and acellular pertussis antigens
12. Question: At what ages are DTaP vaccines recommended in the primary series? Answer: 2 months, 4 months, 6 months, 15-18 months, and 4-6 years
13. Question: What is the difference between DTaP and Tdap vaccines? Answer: DTaP is for children under 7, while Tdap is for adolescents and adults
14. Question: Why is cocooning recommended for pertussis prevention in infants? Answer: To protect infants by vaccinating close contacts who might transmit the disease
15. Question: What percentage of vaccinated children may still get pertussis if exposed? Answer: Approximately 10-20%
16. Question: What is the recommended management for apnea in infants with pertussis? Answer: Hospitalization and close monitoring
17. Question: How long can pertussis bacteria persist in the nasopharynx after infection? Answer: Up to 6 weeks after onset of symptoms
18. Question: What is the role of corticosteroids in treating pertussis? Answer: Limited; not routinely recommended due to lack of proven benefit
19. Question: What is the typical white blood cell count in infants with severe pertussis? Answer: Markedly elevated, often >20,000 cells/μL with lymphocyte predominance
20. Question: How does pertussis transmission occur? Answer: Through respiratory droplets from coughing or sneezing
21. Question: What is the recommended isolation period for hospitalized patients with pertussis? Answer: Until 5 days of appropriate antibiotic therapy have been completed
22. Question: What is the role of cough suppressants in treating pertussis? Answer: Generally not recommended, as they do not affect the course of the disease
23. Question: What is the most common neurologic complication of pertussis in infants? Answer: Seizures
24. Question: How does B. parapertussis infection differ from B. pertussis infection? Answer: Generally milder symptoms and shorter duration
25. Question: What is the estimated global burden of pertussis in children under 5 years old? Answer: Approximately 24.1 million cases and 160,700 deaths per year (as of 2014 WHO estimates)
26. Question: What is the role of maternal Tdap vaccination in preventing infant pertussis? Answer: It provides passive antibody protection to the infant in the first months of life
27. Question: What is the recommended timing for maternal Tdap vaccination? Answer: Between 27 and 36 weeks of each pregnancy
28. Question: What is the significance of pertactin-negative B. pertussis strains? Answer: They may be associated with increased vaccine breakthrough cases
29. Question: What is the role of serology in diagnosing pertussis? Answer: Useful in later stages of illness when PCR and culture may be negative
30. Question: What is the recommended duration of antibiotic treatment for pertussis? Answer: 5 days for azithromycin, 7 days for clarithromycin, or 14 days for erythromycin or trimethoprim-sulfamethoxazole

Disclaimer

The notes provided on Pediatime are generated from online resources and AI sources and have been carefully checked for accuracy. However, these notes are not intended to replace standard textbooks. They are designed to serve as a quick review and revision tool for medical students and professionals, and to aid in theory exam preparation. For comprehensive learning, please refer to recommended textbooks and guidelines.